Neuropace Stock Earnings Reports

NeuroPace reported Q1 2026 revenue of $22.1M (or $22.0M excluding DIXI Medical), driven by RNS System sales ($21.7M), representing ~8% year-over-year growth. The company reached all-time highs in active prescribers, accounts and patient pipeline, with growth concentrated in Level 4 comprehensive epilepsy centers and increasing contributions from community referral channels. Management raised full-year 2026 revenue guidance to $99M–$101M (up from $98M–$100M), reflecting expected underlying RNS growth of 21%–23% (excluding any contribution from a potential IGE indication expansion) and added ~ $500k of anticipated service revenue. Non-GAAP gross margin was ~82.5%; non-GAAP operating expenses were $21.5M. Adjusted EBITDA loss is now expected to be a loss of $8.5M–$9.5M (improved from prior -$9M to -$10M). Cash and equivalents were $54.8M at quarter end. Regulatory update: NeuroPace completed an FDA mid-cycle (day-100) meeting for the NAUTILUS PMA-supplement (IGE indication), has responded to FDA follow-up questions, and remains on track for a midyear determination. Clinical highlights include strong NAUTILUS 18-month results (77% median reduction in generalized tonic-clonic seizures) and a published 3-year post-approval study showing an 82% median seizure reduction in drug-resistant focal epilepsy. Product and AI development remain priorities: ECoG Assistant submission and cloud migration targeted for Q2 2026, and development of a multimodal foundational model is underway leveraging a proprietary intracranial EEG dataset. Management emphasized continued commercial investments (sales hires, incentive alignment, nurse navigators) to reduce funnel friction and increase procedural consistency.